Navigation Links
Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Third Quarter 2009 Financial Results on Tuesday, November 10, 2009 at 8:30 a.m. EST
Date:11/6/2009

NEW YORK, Nov. 6 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) will hold a conference call on Tuesday, November 10, 2009 at 8:30 a.m. EST to discuss the third quarter 2009 financial results and business outlook for the remainder of 2009. Ron Bentsur, Chief Executive Officer of the Company, will host the call. Keryx will announce its financial results for this period in a press release to be issued prior to the call.

In order to participate in the conference call, please call 1-877-869-3847 (U.S.), 1-201-689-8261 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

The press release announcing the Company's financial results for this period will be posted on the Company's website, http://www.keryx.com, prior to the call.

About Keryx Biopharmaceuticals, Inc.

Keryx Biopharmaceuticals is focused on the acquisition, development and commercialization of medically important pharmaceutical products for the treatment of life-threatening diseases, including cancer and renal disease. Keryx is developing KRX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signaling cascade that has been shown to induce cell growth and cell transformation. KRX-0401 has demonstrated both safety and clinical efficacy in several tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number of other key signal transduction pathways, including the JNK and MAPK pathways, which are pathways associated with programmed c
'/>"/>

SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentation of Zerenex (ferric citrate) for the Treatment of Hyperphosphatemia at the Upcoming American Society of Nephrology Renal Week Meeting in San Diego
2. Keryx Reports Results of Open Label Extension Study Examining Long-Term Use of Zerenex, an Iron-Based Phosphate Binder, for the Treatment of Hyperphosphatemia
3. Keryx Biopharmaceuticals Phase 2 Data of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Renal Cell Cancer Selected for Oral Presentation at the Eighth International Kidney Cancer Symposium
4. Keryx Biopharmaceuticals, Inc. Commences Phase 1 Study of KRX-0401 (Perifosine) in Recurrent Pediatric Solid Tumors at Memorial Sloan-Kettering Cancer Center
5. Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
6. Keryx Biopharmaceuticals Reports Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer
7. Keryx Biopharmaceuticals Reports Single Agent Phase 2 Data of KRX-0401 (Perifosine) Further Demonstrating KRX-0401s Activity in the Treatment of Advanced Metastatic Renal Cell Cancer
8. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data on KRX-0401 (Perifosine) in Combination with Bortezomib (+/- Dexamethasone) at the 12th International Multiple Myeloma Meeting
9. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
10. Keryx Biopharmaceuticals, Inc. Announces Phase 2 Results on KRX-0401 (Perifosine) in Patients with Relapsed/Refractory Waldenstroms Macroglobulinemia at the 44th Annual Meeting of the American Society of Clinical Oncology
11. Keryx Biopharmaceuticals, Inc. Announces Poster Presentation Highlighting Observed Clinical Activity of KRX-0401 (Perifosine) at the American Society of Clinical Oncology Meeting in Chicago, Illinois
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 26, 2014 / -- China Nepstar Chain Drugstore Ltd. (NYSE: ... drugstore chain in China based ... the appointment of Ms. Rebecca Yingnan Zhang ... Ms.Zhang has over 20 years of experience ... 1999. Prior to Ms. Zhang,s appointment as the Company,s ...
(Date:11/24/2014)... , Nov. 24, 2014 Juno Therapeutics ... Therapy Designation to the company,s JCAR015 chimeric antigen ... treatment of relapsed or refractory B-cell acute lymphoblastic ... Memorial Sloan Kettering Cancer Center, where Phase 1 ... "The FDA,s action is important news for patients ...
(Date:11/24/2014)... , Nov. 24, 2014  Relmada Therapeutics, Inc. (OTCQB: ... treatment of chronic pain, announced today that Sergio ... at the LD MICRO "MAIN Event" Micro-Cap Growth Conference ... held at the Luxe Sunset Bel Air Hotel, which ... Los Angeles, California . The presentation ...
Breaking Medicine Technology:China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 2China Nepstar Chain Drugstore Appoints Ms. Rebecca Yingnan Zhang as Chief Operating Officer 3Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 2Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 3Relmada Therapeutics To Present At LD MICRO Conference 2
... Sciences Holdings, Inc. (OTC Bulletin Board: ADLS) announced today ... the majority that Restanza(TM) (cethromycin) demonstrated safety for ... pneumonia (CAP) (11 positive, 3 negative, 1 abstaining). ... efficacy in the treatment of CAP (3 positive, 11 ...
... June 2 PharmAthene, Inc. (NYSE Amex: ... countermeasures against biological and chemical threats, today announced ... Biomedical Advanced Research and Development Authority (BARDA) in ... advanced research and development of medical countermeasures for ...
Cached Medicine Technology:Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 2Advanced Life Sciences Announces Outcome of FDA's Anti-Infective Drugs Advisory Committee Review of Restanza(TM) (cethromycin) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 2PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 3PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 4PharmAthene Submits Proposal to BARDA in Response to Broad Agency Announcement for Advanced Research and Development for Valortim(R) 5
(Date:11/26/2014)... The city of San Diego, California, ... forward with a plan to recycle wastewater – also ... Kleyne supports the San Diego plan as part of ... to Kleyne, by recycling water that San Diego already ... be greatly reduced. (Spagat, E, “San Diego looks to ...
(Date:11/26/2014)... 2014 For its December issue ... AIS Report on Blue Cross and Blue Shield Plans* ... the varied strategies the two Blues plans are implementing ... treatments for sleep apnea, ranging from brick-and-mortar retail stores ... linked to increased rates of a variety of serious ...
(Date:11/26/2014)... November 26, 2014 Loffler Companies has ... Week in Imaging, an online information and news publication ... is the sixth consecutive year Loffler has earned this ... , The Elite Dealer Awards honor the best and ... year’s Elite Dealer honorees were chosen for their innovative ...
(Date:11/26/2014)... With a redesign of the practice ... has enhanced the user experience and functionality of ... an online destination for orthopedic and sports medicine knowledge ... new and improved version of the website. The ... ever for current and prospective patients to find answers ...
(Date:11/26/2014)... 26, 2014 With Thousand Oaks cosmetic ... the prosthodontists at the Anacapa Dental Art Institute in Woodland ... can be daunting for some. , That is why they ... they offer. , “No dentist wants cost to come between ... teeth,” said Dr. Mamaly Reshad, partner in the Anacapa Dental ...
Breaking Medicine News(10 mins):Health News:Global fresh water advocate supports San Diego wastewater recycling plan 2Health News:Global fresh water advocate supports San Diego wastewater recycling plan 3Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 2Health News:AIS Newsletter Reports on Strategies Blues Plans Are Implementing to Combat Sleep Apnea 3Health News:Loffler Companies Recognized as an Elite Dealer for Sixth Consecutive Year 2Health News:Los Angeles Orthopedic Surgeon Dr. Steven Meier Announces Relaunch Of Practice Website 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 2Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 3Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 4Health News:Anacapa Dental Art Institute Doctors Offers 6 Tips on How to Pay for Cosmetic, Restorative and Implant Dentistry 5
... Novel HIV Drug to be Studied in Cell ... A $6 million, five-year federal grant to The ... to investigate a novel approach in treating HIV infection ... therapies for psychological and neurological effects in AIDS. ...
... to concerns that the human papillomavirus vaccine might promote ... found that the majority of respondents did not believe ... infections. The study, conducted by University of Illinois ... and in the November issue of the Journal ...
... utter words , THURSDAY, Oct. 15 (HealthDay News) -- ... how the human brain computes language. , "Two central ... study: one, the way in which higher cognitive processes ... two, the nature of what is perhaps the best-known ...
... to curtail secondhand smoke, experts say , , THURSDAY, Oct. ... really do work at reducing heart attacks from secondhand smoke, ... the risk of heart attack by up to 47 ... according to a report released Thursday by the U.S. Institute ...
... ... the life science, engineering and entertainment industries, announced today they have signed an intellectual ... incorporating Microsoft’s SenseCam technology worldwide. , ... Oxford UK (PRWeb UK) October 15, 2009 -- Vicon, developer of ...
... , NEW YORK, Oct. 15 The Nielsen Company ... CLIO Awards , one of the world,s most recognized international advertising ... "The Dr. Oz Show" and featured health expert ... Honorary CLIO Healthcare Award live at the first-ever CLIO Healthcare ...
Cached Medicine News:Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 2Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 3Health News:NeuroAIDS is Target of Federal Grant to Children's Hospital 4Health News:UIC study finds girls aware of HPV vaccine's benefits 2Health News:Brain Yields Up Clues to Language 2Health News:Smoking Bans Reduce Heart Attacks: Study 2Health News:Smoking Bans Reduce Heart Attacks: Study 3Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 2Health News:Vicon Signs License Agreement with Microsoft to Develop New Medical Technology 3Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 2Health News:Dr. Oz, Host of 'The Dr. Oz Show,' to Accept Honorary CLIO Healthcare Award Live at Nielsen's First-Ever CLIO Healthcare Awards Mixer 3